Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 864-871

  Lubel, John S ^a   Angus, Peter W ^b  

^a BOX HILL HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chemotherapy; Hepatitis B; Reactivation hepatitis

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; AZATHIOPRINE; BILIRUBIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LIVER ENZYME; METHOTREXATE; PREDNISONE; RITUXIMAB; TELBIVUDINE; TENOFOVIR; VINCRISTINE; VIRUS DNA; ANTIVIRUS AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HEPATITIS B ANTIBODY;

ALGORITHM; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; B CELL LYMPHOMA; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INFILTRATION; CHEMOTHERAPY; CONCURRENT INFECTION; CYTOMEGALOVIRUS; CYTOREDUCTIVE SURGERY; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HEPATITIS A; HEPATITIS B; HEPATITIS B REACTIVATION; HEPATITIS B VIRUS; HUMAN; INCIDENCE; JAUNDICE; LIVER; LIVER CELL CARCINOMA; LIVER INJURY; LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REVIEW; RISK; SCREENING; SEROCONVERSION; SOLID TUMOR; TREATMENT DURATION; VIRUS REACTIVATION; VIRUS REPLICATION; ARTICLE; DRUG CHOICE; PRACTICE GUIDELINE; RISK FACTOR; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; RISK ASSESSMENT; SECONDARY PREVENTION; VIRUS ACTIVATION; VIRUS LOAD;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 77951754744     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06243.x     Document Type: Review

References (95)

1. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2000 15 (Suppl. E3 6.
2. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996 38 (Suppl. 2 S18 23.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004 11 : 97 107.
4. Yeo W, Chan PK, Hui P et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J. Med. Virol. 2003 70 : 553 561.
5. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975 2 : 528 530.
6. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975 68 : 105 112.
7. Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin. Exp. Rheumatol. 2007 25 : 888 889.
8. Ito S, Nakazono K, Murasawa A et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001 44 : 339 342.
9. Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J. Rheumatol. 1998 25 : 2037 2038.
10. Ojiro K, Naganuma M, Ebinuma H et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J. Gastroenterol. 2008 43 : 397 401.
11. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004 53 : 1363 1365.
12. Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis. 2005 64 : 788 789.
13. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis. 2003 62 : 686 687.
14. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006 43 : 209 220.
15. Yeo W, Zee B, Zhong S et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer 2004 90 : 1306 1311. (Pubitemid 38586252)
16. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000 62 : 299 307.
17. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991 100 : 182 188.
18. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996 78 : 2210 2215.
19. Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann. Oncol. 1997 8 (Suppl. 1 107 109.
20. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin. Oncol. 2004 22 : 927 934. (Pubitemid 41103605)
21. Hsu C, Hsiung CA, Su IJ et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008 47 : 844 853.
22. Takai S, Tsurumi H, Ando K et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur. J. Haematol. 2005 74 : 158 165.
23. Marcucci F, Mele A, Spada E et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006 91 : 554 557.
24. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol. Oncol. 1990 8 : 261 270.
25. Lau GK, Leung YH, Fong DY et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002 99 : 2324 2330.
26. Lau GK, Liang R, Chiu EK, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 1997 19 : 795 799.
27. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J. Clin. Oncol. 1999 17 : 394 398.
28. Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002 36 : 702 709.
29. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004 33 : 925 929.
30. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004 24 : 540 546.
31. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br. J. Cancer 1999 81 : 69 74.
32. Kim MK, Ahn JH, Kim SB et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J. Int. Med. 2007 22 : 237 243.
33. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996 87 : 1202.
34. Tur-Kaspa R, Shaul Y, Moore DD et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988 167 : 630 633.
35. Jang JW, Choi JY, Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004 41 : 427 435.
36. Yeo W, Lam KC, Zee B et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol. 2004 15 : 1661 1666. (Pubitemid 39562607)
37. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006 131 : 59 68.
38. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002 346 : 235 242.
39. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 2004 22 : 4711 4716.
40. Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br. J. Dermatol. 2006 155 : 1053 1056.
41. Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma. Eur. J. Med. Res. 2008 13 : 483 486.
42. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005 46 : 1085 1089.
43. Tsutsumi Y, Kawamura T, Saitoh S et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004 45 : 627 629. (Pubitemid 38196051)
44. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann. Hematol. 2004 83 : 769 774.
45. Ono K, Iyama S, Matsunaga T et al. [Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma]. Gan To Kagaku Ryoho 2007 34 : 1509 1512.
46. Sera T, Hiasa Y, Michitaka K et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Int. Med. 2006 45 : 721 724.
47. Tsutsumi Y, Kanamori H, Mori A et al. Reactivation of hepatitis B virus with rituximab. Expert Opin. Drug Saf. 2005 4 : 599 608.
48. Zhong S, Yeo W, Schroder C et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J. Viral. Hepat. 2004 11 : 55 9.
49. Tanaka Y, Esumi M, Shikata T. Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus. Liver 1990 10 : 6 10.
50. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'? Hepatology 2001 34 : 194 203.
51. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J. Viral. Hepat. 2002 9 : 243 257.
52. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 1996 2 : 1104 1108.
53. Cabrerizo M, Bartolome J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000 32 : 116 123.
54. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993 18 : 1313 1318.
55. Loriot MA, Marcellin P, Walker F et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J. Hepatol. 1997 27 : 251 258.
56. Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008 93 : 951 952.
57. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med. 2001 344 : 68 9.
58. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J. Infect. Chemother. 2005 11 : 189 191.
59. Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003 102 : 1930.
60. Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005 79 : 616 619.
61. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J. Viral. Hepat. 2007 14 : 478 483.
62. Seth P, Alrajhi AA, Kagevi I et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant. 2002 30 : 189 194.
63. Goyama S, Kanda Y, Nannya Y et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002 43 : 2159 2163.
64. Berger A, Preiser W, Kachel HG, Sturmer M, Doerr HW. HBV reactivation after kidney transplantation. J. Clin. Virol. 2005 32 : 162 165.
65. Duhart BT Jr., Honaker MR, Shokouh-Amiri MH et al. Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. Transpl. Infect. Dis. 2003 5 : 126 131.
66. Cil T, Altintas A, Pasa S, Bayan K, Ozekinci T, Isikdogan A. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy. Leuk Lymphoma 2008 49 : 939 947.
67. Lau GK, Lie A, Liang R. Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy. Blood 2002 100 : 3054.
68. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol. 2001 115 : 58 62.
69. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am. J. Gastroenterol. 1999 94 : 249 251.
70. Yeo W, Steinberg JL, Tam JS et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J. Med. Virol. 1999 59 : 263 269.
71. Simpson ND, Simpson PW, Ahmed AM et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. J. Clin. Gastroenterol. 2003 37 : 68 71.
72. Lim LL, Wai CT, Lee YM et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment. Pharmacol. Ther. 2002 16 : 1939 1944.
73. Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series. Am. J. Hematol. 2005 80 : 197 203.
74. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int. 2008 28 : 28 38.
75. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 2008 148 : 519 528.
76. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 125 : 1714 1722.
77. Kim JS, Hahn JS, Park SY et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Med. J. 2007 48 : 78 89.
78. Law JK, Ali JA, Harrigan PR, Sherlock CH, Savage KJ, Yoshida EM. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am. J. Hematol. 2006 81 : 969 972.
79. Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N. Engl. J. Med. 2005 352 : 310 311.
80. Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2006 37 : 625 626.
81. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006 44 : 283 290.
82. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin. Liver Dis. 2007 11 : 965 991, x.
83. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment. Pharmacol. Therap. 2006 24 : 1003 1016.
84. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003 125 : 1742 1749.
85. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J. Viral. Hepat. 2008 15 : 89 102.
86. Barclay S, Pol S, Mutimer D et al. Erratum to "The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting" [J. Clin. Virol. 41 (4) 2008 243-254]. J. Clin. Virol. 2008 42 : 104 115.
87. Liu CJ, Kao JH, Chen DS. Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. Gastroenterology 2006 131 : 1656 author reply -7.
88. Hui CK, Cheung WW, Au WY et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005 54 : 1597 1603.
89. Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int. J. Hematol. 2005 81 : 349 351.
90. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002 51 : 597 599.
91. Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007 46 : 1049 1056.
92. Yeo W, Ho WM, Hui P et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 2004 88 : 209 215.
93. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br. J. Haematol. 2002 116 : 166 169.
94. Stroffolini T, Andriani A, Bibas M, Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann. Hematol. 2002 81 : 48 9.
95. Al-Taie OH, Mork H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann. Hematol. 1999 78 : 247 249.